bispecific antibodies

Roche's bispecific matches Regeneron's Eylea in phase 3 trials
Roche's bispecific matches Regeneron's Eylea in phase 3 trials
Fierce Biotech
Roche
faricimab
diabetic macular edema
clinical trials
Regeneron
Eylea
bispecific antibodies
Flag link:
J&J taps the bispecific experts at Xencor for prostate cancer discovery pact, kicking off with $50M upfront
J&J taps the bispecific experts at Xencor for prostate cancer discovery pact, kicking off with $50M upfront
Endpoints
JNJ
Xencor
Janssen
bispecific antibodies
prostate cancer
Flag link:
AbCellera acquires OrthoMab bispecific platform from Dualogics
AbCellera acquires OrthoMab bispecific platform from Dualogics
Pharmaceutical Business Review
AbCellera
OrthoMab
bispecific antibodies
Dualogics
Flag link:
Amgen tosses back unwanted bispecific to Xencor as KRAS data on track for 2020 readout
Amgen tosses back unwanted bispecific to Xencor as KRAS data on track for 2020 readout
Fierce Biotech
Amgen
bispecific antibodies
Xencor
Flag link:
Merck KGaA picks up another anticancer bispecific from F-star
Merck KGaA picks up another anticancer bispecific from F-star
Fierce Biotech
Merck KGaA
F-star Therapeutics
immuno-oncology
bispecific antibodies
Flag link:
Over a decade ago, a disastrous trial killed research on a potential immunotherapy. Can a Regeneron bispecific revive it?
Over a decade ago, a disastrous trial killed research on a potential immunotherapy. Can a Regeneron bispecific revive it?
Endpoints
immunotherapy
Regeneron
clinical trials
bispecific antibodies
Flag link:
AbbVie to pay Genmab $750M upfront to form bispecific R&D pact
AbbVie to pay Genmab $750M upfront to form bispecific R&D pact
Fierce Biotech
AbbVie
bispecific antibodies
cancer
Genmab
Regeneron
epcoritamab
Flag link:
Sanofi sharpens focus on bispecifics, and China, with Alphamab deal
Sanofi sharpens focus on bispecifics, and China, with Alphamab deal
Endpoints
Sanofi
China
Alphamab Oncology
breast cancer
bispecific antibodies
Flag link:
Roche pens $2B biobucks pact with Innovent Biologics for bispecific and cell therapies
Roche pens $2B biobucks pact with Innovent Biologics for bispecific and cell therapies
Fierce Biotech
Roche
Innovent Biologics
China
bispecific antibodies
cell therapy
Flag link:
Johnson & Johnson's Oncology Team Posts Promising Cancer Trial Results
Johnson & Johnson's Oncology Team Posts Promising Cancer Trial Results
Motley Fool
JNJ
Multiple Myeloma
bispecific antibodies
JNJ-5957
teclistamab
clinical trials
Flag link:
Roche flashes new 16-week bispecific AMD data, setting eyes on pair of PhIII trials
Roche flashes new 16-week bispecific AMD data, setting eyes on pair of PhIII trials
Endpoints
Roche
clinical trials
bispecific antibodies
faricimab
wet age-related macular degeneration
Flag link:
ASH2019 – Regeneron takes the bispecific baton and runs
ASH2019 – Regeneron takes the bispecific baton and runs
EP Vantage
ASH2019
Regeneron
Xencor
bispecific antibodies
REGN1979
lyphoma
Flag link:
ASH: Amgen's BiTE stalls multiple myeloma relapse in mice in combo with BMS' Revlimid
ASH: Amgen's BiTE stalls multiple myeloma relapse in mice in combo with BMS' Revlimid
Fierce Biotech
Amgen
ASH2019
bispecific antibodies
AMG 701
Multiple Myeloma
Flag link:
Merus charts early promise for cancer drug targeting NRG1 fusions
Merus charts early promise for cancer drug targeting NRG1 fusions
Fierce Biotech
Merus
bispecific antibodies
zenocutuzumab
NRG1 fusion
Flag link:
UCB's bispecific beats J&J's Stelara in psoriasis phase 3
UCB's bispecific beats J&J's Stelara in psoriasis phase 3
Fierce Biotech
UCB Pharma
bispecific antibodies
bimekizumab
JNJ
Stelara
psoriasis
Flag link:
Glenmark spin-out aims to challenge Amgen, others in cancer bispecific field
Glenmark spin-out aims to challenge Amgen, others in cancer bispecific field
Biopharma Dive
Glenmark
Ichnos Sciences
India
Amgen
oncology
Regeneron
bispecific antibodies
Flag link:
Overcoming Cancer Drug Resistance with A Bispecific Inhibitor
Overcoming Cancer Drug Resistance with A Bispecific Inhibitor
Xtalks
oncology
drug resistance
Kitov
cancer
bispecific antibodies
Flag link:
Lilly drops PD-L1/TIM-3 bispecific from clinical pipeline
Lilly drops PD-L1/TIM-3 bispecific from clinical pipeline
Fierce Biotech
Eli Lilly
bispecific antibodies
solid tumors
Flag link:
Affimed scraps T-cell engager program, parts company with CSO
Affimed scraps T-cell engager program, parts company with CSO
Fierce Biotech
Affimed
bispecific antibodies
T-cell engager
cancer
Flag link:
Merck KGaA retools F-star pact, walks away from lead PD-L1 drug
Merck KGaA retools F-star pact, walks away from lead PD-L1 drug
Fierce Biotech
Merck KGaA
bispecific antibodies
f-star
drug discovery
Flag link:

Pages